Tsumura & Co. (TYO:4540)
Japan · Delayed Price · Currency is JPY 3,852.00
+67.00 (1.77%)
Nov 21, 2025, 3:30 PM JST
Tsumura & Co. Revenue
Tsumura & Co. had revenue of 46.80B JPY in the quarter ending September 30, 2025, with 3.13% growth. This brings the company's revenue in the last twelve months to 181.92B, up 10.51% year-over-year. In the fiscal year ending March 31, 2025, Tsumura & Co. had annual revenue of 181.09B with 20.05% growth.
Revenue (ttm)
181.92B
Revenue Growth
+10.51%
P/S Ratio
1.57
Revenue / Employee
42.58M
Employees
4,272
Market Cap
286.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 181.09B | 30.25B | 20.05% |
| Mar 31, 2024 | 150.85B | 10.80B | 7.71% |
| Mar 31, 2023 | 140.04B | 10.50B | 8.10% |
| Mar 31, 2022 | 129.55B | -1.34B | -1.02% |
| Mar 31, 2021 | 130.88B | 7.64B | 6.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |